Balyasny Asset Management
AMLX icon

Balyasny Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Balyasny Asset Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.3M Sell
684,974
-422,297
-38% -$6.53M 0.02% 966
2026
Q1 		$15.4M Buy
1,107,271
+248,587
+29% +$3.5M 0.02% 803
2025
Q4 		$10.4M Sell
858,684
-617,618
-42% -$8.39M 0.01% 1007
2025
Q3 		$20.1M Buy
+1,476,302
New +$13.9M 0.03% 716
2025
Q2 		– Sell
-148,559
Closed -$526K – 2771
2025
Q1 		$526K Buy
148,559
+98,311
+196% +$350K ﹤0.01% 2253
2024
Q4 		$190K Sell
50,248
-655
-1% -$3.08K ﹤0.01% 2536
2024
Q3 		$165K Buy
50,903
+28,016
+122% +$63K ﹤0.01% 2595
2024
Q2 		$43.5K Buy
+22,887
New +$44.4K ﹤0.01% 2442
2024
Q1 		– Sell
-19,698
Closed -$290K – 2580
2023
Q4 		$290K Sell
19,698
-677,183
-97% -$10.4M ﹤0.01% 2173
2023
Q3 		$12.8M Sell
696,881
-476,972
-41% -$10.1M 0.03% 752
2023
Q2 		$25.3M Buy
1,173,853
+753,012
+179% +$20.3M 0.06% 449
2023
Q1 		$12.3M Sell
420,841
-224,712
-35% -$7.81M 0.03% 700
2022
Q4 		$23.9M Buy
645,553
+454,219
+237% +$16.1M 0.07% 418
2022
Q3 		$5.39M Buy
+191,334
New +$4.77M 0.02% 951
2022
Q2 		– Sell
-62,915
Closed -$808K – 2720
2022
Q1 		$808K Buy
+62,915
New +$1.42M ﹤0.01% 1692

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Balyasny Asset Management's AMLX Position: Q2 2026 in Review

Balyasny Asset Management reduced its Amylyx Pharmaceuticals (AMLX) stake by 38% in Q2 2026, selling an estimated $6.53M and leaving 684,974 shares worth $12.3M. The position accounts for 0.02% of the portfolio, ranked #966.

Balyasny Asset Management first reported a position in AMLX in Q1 2022 and has held it in 15 quarters since. The position peaked at $25.3M in Q2 2023. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Balyasny Asset Management held 684,974 shares of Amylyx Pharmaceuticals worth $12.3M as of Q2 2026.
  • Balyasny Asset Management sold 422,297 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $6.53M.
  • Amylyx Pharmaceuticals made up 0.02% of Balyasny Asset Management's portfolio in Q2 2026, its #966 holding.
  • Balyasny Asset Management first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 15 quarters since.
  • Balyasny Asset Management's Amylyx Pharmaceuticals position peaked at $25.3M in Q2 2023.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.